iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's disease.

Parkinson's disease (PD) has been attributed to a combination of genetic and nongenetic factors. We studied a set of monozygotic twins harboring the heterozygous glucocerebrosidase mutation (GBA N370S) but clinically discordant for PD. We applied induced pluripotent stem cell (iPSC) technology for PD disease modeling using the twins' fibroblasts to evaluate and dissect the genetic and nongenetic contributions. Utilizing fluorescence-activated cell sorting, we obtained a homogenous population of "footprint-free" iPSC-derived midbrain dopaminergic (mDA) neurons. The mDA neurons from both twins had ∼50% GBA enzymatic activity, ∼3-fold elevated α-synuclein protein levels, and a reduced capacity to synthesize and release dopamine. Interestingly, the affected twin's neurons showed an even lower dopamine level, increased monoamine oxidase B (MAO-B) expression, and impaired intrinsic network activity. Overexpression of wild-type GBA and treatment with MAO-B inhibitors normalized α-synuclein and dopamine levels, suggesting a combination therapy for the affected twin.

[1]  Nicholas Eriksson,et al.  Web-Based Genome-Wide Association Study Identifies Two Novel Loci and a Substantial Genetic Component for Parkinson's Disease , 2011, PLoS genetics.

[2]  Patrick A. Lewis,et al.  Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus , 2011, Nature communications.

[3]  Sunhong Kim,et al.  Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin , 2006, Nature.

[4]  Werner Poewe,et al.  A double-blind, delayed-start trial of rasagiline in Parkinson's disease. , 2009, The New England journal of medicine.

[5]  P. Pollak,et al.  Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers , 2012, Neurology.

[6]  S. Tabrizi,et al.  Correction: PINK1 Is Necessary for Long Term Survival and Mitochondrial Function in Human Dopaminergic Neurons , 2008, PLoS ONE.

[7]  Zhen Yan,et al.  Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells , 2012, Nature Communications.

[8]  Blake Byers,et al.  LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. , 2011, Cell stem cell.

[9]  Ying Sun,et al.  Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies , 2011, Cell.

[10]  J. Hardy,et al.  Glucocerebrosidase Deficiency in Substantia Nigra of Parkinson Disease Brains , 2012, Annals of neurology.

[11]  J W Langston,et al.  Parkinson disease in twins: an etiologic study. , 1999, JAMA.

[12]  A. Schapira,et al.  Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Disease—Links to Parkinson’s Disease , 2013, Cell metabolism.

[13]  O. Isacson,et al.  Markers and Methods for Cell Sorting of Human Embryonic Stem Cell‐Derived Neural Cell Populations , 2007, Stem cells.

[14]  Ronald Melki,et al.  Neuron‐to‐neuron transmission of α‐synuclein fibrils through axonal transport , 2012, Annals of neurology.

[15]  M. Nalls,et al.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. , 2009, The New England journal of medicine.

[16]  Stormy J. Chamberlain,et al.  Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader–Willi syndromes , 2010, Proceedings of the National Academy of Sciences.

[17]  D. Surmeier,et al.  Floor plate-derived dopamine neurons from hESCs efficiently engraft in animal models of PD , 2011, Nature.

[18]  Ying Sun,et al.  Acid β‐glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter α‐synuclein processing , 2011, Annals of neurology.

[19]  E. Sidransky,et al.  Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders , 2010, Acta Neuropathologica.

[20]  K. Marder,et al.  Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. , 2010, Archives of neurology.

[21]  J. Rothstein,et al.  Epigenetic regulation of neuron‐dependent induction of astroglial synaptic protein GLT1 , 2009, Glia.

[22]  M. Memo,et al.  Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease , 2012, EMBO molecular medicine.

[23]  F. Gage,et al.  Cell-Surface Marker Signatures for the Isolation of Neural Stem Cells, Glia and Neurons Derived from Human Pluripotent Stem Cells , 2011, PloS one.

[24]  John R. Yates,et al.  Isogenic Human iPSC Parkinson’s Model Shows Nitrosative Stress-Induced Dysfunction in MEF2-PGC1α Transcription , 2013, Cell.

[25]  Christine Klein,et al.  Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson’s Disease , 2012, Science Translational Medicine.

[26]  H. Okano,et al.  Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue , 2012, Molecular Brain.

[27]  Torsten Kluba,et al.  Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. , 2013, Cell stem cell.

[28]  G. Wenning,et al.  Expression of early developmental markers predicts the efficiency of embryonic stem cell differentiation into midbrain dopaminergic neurons. , 2013, Stem cells and development.

[29]  A. Björklund,et al.  Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons , 2012, Proceedings of the National Academy of Sciences.

[30]  S. Lipton,et al.  Isogenic Human iPSC Parkinson’s Model Shows Nitrosative Stress-Induced Dysfunction in MEF2-PGC1α Transcription , 2013, Cell.

[31]  Akira Wada,et al.  DNA Methylation of the Monoamine Oxidases A and B Genes in Postmortem Brains of Subjects with Schizophrenia , 2012 .

[32]  M. Tomishima,et al.  Identification of embryonic stem cell-derived midbrain dopaminergic neurons for engraftment. , 2012, The Journal of clinical investigation.

[33]  Chuong B. Do,et al.  Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database , 2012, PLoS genetics.

[34]  N. Pedersen,et al.  Heritability of Parkinson disease in Swedish twins: a longitudinal study , 2011, Neurobiology of Aging.

[35]  R. Sidman,et al.  CNS expression of glucocerebrosidase corrects α-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy , 2011, Proceedings of the National Academy of Sciences.